Takeda Pharmaceutical Co. Ltd. has entered into a licensing agreement with Alnylam Pharmaceuticals to secure rights to RNA interference technology. Alnylam, which said it may receive as much as $1 billion from the deal, will work with Takeda for five years to develop RNAi-based therapies, specifically to treat cancer and metabolic diseases.

Related Summaries